相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Engineered Fibroblast Growth Factor 19 Reduces Liver Injury and Resolves Sclerosing Cholangitis in Mdr2-Deficient Mice
Mei Zhou et al.
HEPATOLOGY (2016)
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Steven A. Kliewer et al.
DIGESTIVE DISEASES (2015)
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Jessica Zucman-Rossi et al.
GASTROENTEROLOGY (2015)
Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site
Vijay K. Ulaganathan et al.
NATURE (2015)
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al.
NATURE GENETICS (2015)
FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis
Rachel J. Perry et al.
NATURE COMMUNICATIONS (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Mei Zhou et al.
CANCER RESEARCH (2014)
Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells
Shanshan Wan et al.
GASTROENTEROLOGY (2014)
Genomic Portrait of Resectable Hepatocellular Carcinomas: Implications of RB1 and FGF19 Aberrations for Patient Stratification
Sung-Min Ahn et al.
HEPATOLOGY (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Hua Yu et al.
NATURE REVIEWS CANCER (2014)
Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling
Guobin He et al.
CELL (2013)
Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma
Jiyeon Hyeon et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
FGF19 action in the brain induces insulin-independent glucose lowering
Gregory J. Morton et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
NAFLD, NASH and liver cancer
Gregory A. Michelotti et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
Seiki Miura et al.
BMC CANCER (2012)
Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin-6-signaling pathway
Yun Shin Chun et al.
HEPATOLOGY (2012)
Obesity, inflammation, and liver cancer
Beicheng Sun et al.
JOURNAL OF HEPATOLOGY (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
Dorothy M. French et al.
PLOS ONE (2012)
Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System
Maria U. Latasa et al.
PLOS ONE (2012)
Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys
Rama Pai et al.
TOXICOLOGICAL SCIENCES (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Emilie A. Bard-Chapeau et al.
CANCER CELL (2011)
FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
Matthew J. Potthoff et al.
CELL METABOLISM (2011)
CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation
Terence Kin Wah Lee et al.
CELL STEM CELL (2011)
Alpha-Fetoprotein Should Be Included in the Hepatocellular Carcinoma Surveillance Guidelines of the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2011)
CURRENT CONCEPTS Hepatocellular Carcinoma
Hashem B. El-Serag
NEW ENGLAND JOURNAL OF MEDICINE (2011)
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Serkan Kir et al.
SCIENCE (2011)
Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation
Guobin He et al.
CANCER CELL (2010)
Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression
Eek Joong Park et al.
CELL (2010)
Interleukin-6 Signaling in Liver-Parenchymal Cells Suppresses Hepatic Inflammation and Improves Systemic Insulin Action
F. Thomas Wunderlich et al.
CELL METABOLISM (2010)
miR-130b Promotes CD133+ Liver Tumor-Initiating Cell Growth and Self-Renewal via Tumor Protein 53-Induced Nuclear Protein 1
Stephanie Ma et al.
CELL STEM CELL (2010)
Liver-Directed Recombinant Adeno-Associated Viral Gene Delivery Rescues a Lethal Mouse Model of Methylmalonic Acidemia and Provides Long-Term Phenotypic Correction
Nuria Carrillo-Carrasco et al.
HUMAN GENE THERAPY (2010)
EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
Taro Yamashita et al.
GASTROENTEROLOGY (2009)
High Expression of the Bile Salt-Homeostatic Hormone Fibroblast Growth Factor 19 in the Liver of Patients with Extrahepatic Cholestasis
Frank G. Schaap et al.
HEPATOLOGY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Significance of CD90+ cancer stem cells in human liver cancer
Zhen Fan Yang et al.
CANCER CELL (2008)
Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling
Rama Pai et al.
CANCER RESEARCH (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
C. Porta et al.
ANNALS OF ONCOLOGY (2008)
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
Lr Desnoyers et al.
ONCOGENE (2008)
Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery
Akira Moh et al.
LABORATORY INVESTIGATION (2007)
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production
Willscott E. Naugler et al.
SCIENCE (2007)
Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells
Souvik Chattopadhyay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Hepatocellular carcinoma: Recent trends in the United States
HB El-Serag
GASTROENTEROLOGY (2004)
Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation
S Radaeva et al.
HEPATOLOGY (2004)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Interleukin-21 is a growth and survival factor for human myeloma cells
AT Brenne et al.
BLOOD (2002)
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity
E Tomlinson et al.
ENDOCRINOLOGY (2002)
分享论文
